Evidence map›Paper›PMID 36845852›Full record

ArticleTransplantation direct2023

Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study.

Michele Malagola, Nicola Polverelli, Massimo Martino, Francesca Patriarca, Benedetto Bruno, Luisa Giaccone, Giovanni Grillo, Stefania Bramanti, Paolo Bernasconi, Marco De Gobbi and 27 more

Abstract read
In one paragraph

Article in Transplantation direct, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Michele MalagolaDepartment of Clinical and Experimental Sciences, Blood Diseases and Cell Therapies Unit, Bone Marrow Transplant Unit, "Azienda Socio Santiaria Territoriale Spedali Civili" Hospital of Brescia, University of Brescia, Brescia, Italy.
Nicola PolverelliDepartment of Clinical and Experimental Sciences, Blood Diseases and Cell Therapies Unit, Bone Marrow Transplant Unit, "Azienda Socio Santiaria Territoriale Spedali Civili" Hospital of Brescia, University of Brescia, Brescia, Italy.
Massimo MartinoStem Cell Transplant and Cellular Therapies Unit, "Bianco Melacrino Morelli" Hospital, Reggio Calabria, Italy.
Francesca PatriarcaHaematological Clinic and Transplant Centre, University Hospital of Central Friuli, Dipartimento Area Medica, University of Udine, Udine, Italy.
Benedetto BrunoDepartment of Oncology, Struttura Semplice Dipartimentale Allogeneic Stem Cell Transplantation, "Città della Salute e della Scienza" University Hospital Centre in Turin, Turin, Italy.
Luisa GiacconeDepartment of Oncology, Struttura Semplice Dipartimentale Allogeneic Stem Cell Transplantation, "Città della Salute e della Scienza" University Hospital Centre in Turin, Turin, Italy.
Giovanni GrilloDivision of Haematology and Marrow Transplants, Niguarda Hospital, Milan, Italy.
Stefania BramantiIstituto di Ricerca e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano, Milan, Italy.
Paolo BernasconiTransplant Centre, Unit of Haematology Foundation Istituto di Ricerca e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.
Marco De GobbiDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Annalisa NataleHaematological Intensive Care, Pescara Hospital, Pescara, Italy.
Elisabetta TerruzziHaematology Unit, San Gerardo Hospital, Monza, Italy.
Attilio OlivieriHaematology Clinc, "Ospedali Riuniti" University Hospital of Ancona, Ancona, Italy.
Patrizia ChiusoloDepartment of Medical Imaging, Radiotherapy, Oncology and Haematology, "A. Gemelli Istituto di Ricerca e Cura a Carattere Scientifico" University Teaching Hospital Foundation, Rome, Italy.
Angelo Michele CarellaStruttura Semplice Dipartimentale Haematological Intensive Care and Cell Therapy Unit, Department of Medical Sciences, "Casa Sollievo della Sofferenza" Foundation, San Giovanni Rotondo, Italy.
Marco CasiniHaematology and Bone Marrow Transplantation, Bolzano Hospital, Bolzano, Italy.
Enrico MaffiniIstituto di Ricerca e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Chiara NozzoliCell Therapy and Transfusion Medicine, "Careggi" University Hospital, Florence, Italy.
Patrizio MazzaPO San Giuseppe Moscati, Transplant Division, Department of Haematology, ASL Taranto, Italy.
Simona BassiHaematology Unit, "G. da Saliceto" Hospital, Piacenza, Italy.
Francesco OnidaIstituto di Ricerca e Cura a Carattere Scientifico Foundation "Ospedale Maggiore Ca' Granda Policlinico," University of Milan, Italy.
Adriana VaccaHematology Unit, Centro Trapianti di Midollo Osseo P.O. " A. Businco", ARNAS Brotzu, Cagliari, Italy.
Sadia FalcioniUnit of Haematology and Cell Therapy, "C. e G. Mazzoni" Hospital, Ascoli Piceno, Italy.
Mario LuppiDivision of Hematology Azienda Ospedaliero-Universitaria Modena, Department of Medical and Surgical Sciences, Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
Anna Paola IoriDepartment of Haematology, Oncology and Dermatology, "Umberto I" University Hospital, Roma Sapienza University, Rome, Italy.
Vincenzo PavoneDepartment of Haematology and Bone Marrow Transplantation, "Card. G. Panico" Hospital, Tricase, Italy.
Cristina SkertUnit of Haematology/Bone Marrow Transplantation, Unit "Ospedale dell'Angelo", Venice, Mestre, Italy.
Paola CarluccioDepartment of Emergency and Organ Transplantation, Haematology and Stem Cell Transplantation Unit, "Aldo Moro" University of Bari, Bari, Italy.
Carlo BorgheroHaematology Department, "San Bortolo" Hospital, Vicenza, Italy.
Anna ProiaUnit of Haematology and Stem Cell Transplant Centre, "San Camillo" Hospital, Rome, Italy.
Carmine Selleri"San Giovanni di Dio e Ruggi d'Aragona" University Hospital, Salerno, Italy.
Vicky RubiniUniversity of Milan, Italy.
Nicoletta SacchiItalian Bone Marrow Donor Registry, E.O. Galliera Hospitals, Genoa, Italy.
Elena OldaniHaematology Unit, "Azienda Socio Santiaria Territoriale Papa Giovanni XXIII", Bergamo, Italy.
Francesca BonifaziIstituto di Ricerca e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Fabio CiceriDepartment of Onco-Haematology, Haematology and Bone Marrow Transplantation, Istituto di Ricerca e Cura a Carattere Scientifico San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.
Domenico RussoDepartment of Clinical and Experimental Sciences, Blood Diseases and Cell Therapies Unit, Bone Marrow Transplant Unit, "Azienda Socio Santiaria Territoriale Spedali Civili" Hospital of Brescia, University of Brescia, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The conditioning regimens with different alkylators at different doses can influence the outcome of allogeneic stem cell transplantation (SCT), but conclusive data are missing. Methods: With the aim to analyze real-life allogeneic SCTs performed in Italy between 2006 and 2017 in elderly patients (aged >60 y) with acute myeloid leukemia or myelodysplastic syndrome, we collected 780 first transplants data. For analysis purposes, patients were grouped according to the type of alkylator included in the conditioning (busulfan [BU]-based; n = 618; 79%; treosulfan [TREO]-based; n=162; 21%). Results: No significant differences were observed in nonrelapse mortality, cumulative incidence of relapse, and overall survival, although in the TREO-based group, we observed a greater proportion of elderly patients ( Conclusions: Despite a higher number of risk factors in the TREO group, no significant differences were observed in nonrelapse mortality, cumulative incidence of relapse, and overall survival according to the type of alkylator, suggesting that TREO has no advantage over BU in terms of efficacy and toxicity in acute myeloid leukemia and myelodysplastic syndrome.

Identifiers

PMID36845852
PMCPMC9949804

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.